EICHOR
● Active Not Recruiting
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
Condition: Multiple Sclerosis · Sponsor: Hoffmann-La Roche
About this study
This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with PPMS, in comparison to the approved 600 milligrams (mg) dose of ocrelizumab.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (147)
| Alabama Neurology Associates | Homewood, Alabama, United States | — |
| 21st Century Neurology | Phoenix, Arizona, United States | — |
| University of California Irvine | Irvine, California, United States | — |
| Stanford University Medical Center | Stanford, California, United States | — |
| University of Colorado Denver | Aurora, Colorado, United States | — |
| Advanced Neurosciences Research LLC | Fort Collins, Colorado, United States | — |
| MS and Neuromuscular Center of Excellence | Clearwater, Florida, United States | — |
| University of South Florida | Tampa, Florida, United States | — |
| Baptist Health Lexington | Nicholasville, Kentucky, United States | — |
| International Neurorehabilitation Institute | Lutherville, Maryland, United States | — |
| Massachusetts General Hospital. | Boston, Massachusetts, United States | — |
| University of Massachusetts Medical School | Worcester, Massachusetts, United States | — |
+ 135 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04548999